MedTrace Logo

Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children

NCT00580684 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2007-12-27

No results posted yet for this study

Summary

To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.

Conditions

  • Vaccines, Pneumococcal
  • Vaccines, Pneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL

pneumococcus conjugate vaccine 7 valent to reduce carriage

plain polisacaride vaccine 23 valent to reduce carriage

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Completion
2004-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00580684 on ClinicalTrials.gov